IL-1 BINDING PROTEINS

The present invention describes IL-1beta binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1beta. Binding proteins of the invention have high affinity for IL-1beta and neutralize IL-1beta activity. A binding protein of the invention can be a full-length antibod...

Full description

Saved in:
Bibliographic Details
Main Authors WU CHENGBIN, HSIEH CHUNG MING, MILLER RENEE, AMBROSI DOMINIC J
Format Patent
LanguageEnglish
Korean
Published 21.09.2012
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention describes IL-1beta binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1beta. Binding proteins of the invention have high affinity for IL-1beta and neutralize IL-1beta activity. A binding protein of the invention can be a full-length antibody or an IL-1beta-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1beta binding proteins of the invention are useful for detecting IL-1beta and for inhibiting IL-1beta activity, including in a human subject suffering from a disease or disorder in which IL-1beta activity is detrimental.
Bibliography:Application Number: KR20127012405